M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief Executive Officer Kyle Gano and Chief ...

RBC Capital lowered the firm’s price target on Neurocrine (NBIX) to $139 from $148 and keeps a Sector Perform rating on the shares. The payer ...

Charles Schwab Investment Management Inc. raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by ...

The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.

Neurocrine Biosciences enters 2025 with strong momentum from record-breaking 2024 INGREZZA sales and promising early indicators for CRENESSITY’s launch. While the company faces competitive and ...

E ric Benevich, the Chief Commercial Officer of Neurocrine Biosciences Inc (NASDAQ:NBIX), recently disclosed significant stock transactions. According to a Form 4 filing with the Securities and ...

Morgan Stanley assumed coverage of Neurocrine (NBIX) with an Overweight rating and a price target of $150, down from $185. The firm sees ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates. Overall, the quarter showcased strong ...

SAN DIEGO, March 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability ...

SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18 ...